TG THERAPEUTICS, INC. Net Income (Loss) Available to Common Stockholders, Basic
TG THERAPEUTICS, INC. (TGTX) reported Net Income (Loss) Available to Common Stockholders, Basic of -$551.74 thousand for the 3-month period ending 2011-09-30, per its 10-Q filed 2011-11-14.
Discontinued › Income Statement › Net Income
us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic · last filed 2011-11-14
- TG THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2011-09-30 was -$551.74K, a 1437.65% decline year-over-year.
- TG THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2011-06-30 was -$2.98M, a 261.19% decline year-over-year.
- TG THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2010-09-30 was $41.25K.
- TG THERAPEUTICS, INC. net income (loss) available to common stockholders, basic for the quarter ending 2010-06-30 was $1.85M.
| Period end | Net Income (Loss) Available to Common Stockholders, Basic 3 month | Net Income (Loss) Available to Common Stockholders, Basic 6 month | Net Income (Loss) Available to Common Stockholders, Basic 9 month | Net Income (Loss) Available to Common Stockholders, Basic 119 month | Net Income (Loss) Available to Common Stockholders, Basic 122 month |
|---|---|---|---|---|---|
| 2011-09-30 | -$551.74K 10-Q · filed 2011-11-14 | -$3.53M derived: sum of 2 quarters · filed 2011-11-14 | $298.11K 10-Q · filed 2011-11-14 | -$61.01M 10-Q · filed 2011-11-14 | |
| 2011-06-30 | -$2.98M 10-Q/A · filed 2011-09-14 | $849.84K 10-Q/A · filed 2011-09-14 | -$60.46M 10-Q/A · filed 2011-09-14 | ||
| 2010-09-30 | $41.25K 10-Q · filed 2011-11-14 | $1.89M derived: sum of 2 quarters · filed 2011-11-14 | $258.41K 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | $1.85M 10-Q/A · filed 2011-09-14 | $217.17K 10-Q/A · filed 2011-09-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Praxis Precision Medicines, Inc. (PRAX) | United States | $7.884B | -27.60 |
| Structure Therapeutics Inc. (GPCR) | United States | $7.710B | -53.41 |
| Spyre Therapeutics, Inc. (SYRE) | United States | $7.685B | -43.69 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| IONIS PHARMACEUTICALS INC (IONS) | United States | $7.277B | -23.25 |
| Alkermes plc. (ALKS) | $6.844B | 132.74 | |
| RHYTHM PHARMACEUTICALS, INC. (RYTM) | United States | $6.771B | -37.20 |